Discovery and Design of Inhibitors of Oncogenic Tyrosine Kinases

  • Paul Workman
  • Valerie G. Brunton
  • David J. Robins
Part of the ESO Monographs book series (ESO MONOGRAPHS)


The recognition that we may be approaching a plateau of effectiveness with traditional anticancer agents has led to the view that to gain more than incremental value against the major solid tumours will require a radically different strategy. Rather than the “black box” approach of random screening for cytotoxicity or cytostasis, or even the rational design of improved agents acting on conventional drug targets [1,2], many believe that this quantum leap will come from an exploitation of the identification of the genes and their encoded protein products which control proliferation, differentiation and cell death, combined with an understanding of their aberrant behaviour in malignant cells. Cancer is now described in extraordinary detail at the molecular level as a genetic disease. As a result of the remarkable advances in molecular oncology made over the last few years, the new central dogma of cancer drug discovery can be defined as: new biology → new targets → new therapies [3].


Epidermal Growth Factor Receptor Tyrosine Kinase Tyrosine Kinase Inhibitor Focal Adhesion Kinase Tyrosine Protein Kinase Inhibitor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Johnson RK: Screening methods in drug discovery. JNCI 1990 (82):1082–1083PubMedGoogle Scholar
  2. 2.
    Schwartsmann G and Workman P: Anticancer drug screening and discovery in the 1990s: A European perspective. Eur J Cancer 1993 (29A):3–14CrossRefGoogle Scholar
  3. 3.
    Workman P (ed) New anticancer drug design based on advances in molecular oncology. Sem Cancer Biol 1992 (3):329–333Google Scholar
  4. 4.
    Vogelstein B and Kinzler KW: The multistep nature of cancer. Trends Genetics 1993 (9):138–141CrossRefGoogle Scholar
  5. 5.
    Powis G: Signalling targets for anticancer drug development. Trends Pharm Sci 1991 (12):188–193PubMedCrossRefGoogle Scholar
  6. 6.
    Brunton VG and Workman P: Cell-signalling targets for antitumour drug development. Cancer Chemother Pharmacol 1993 (32):1–19PubMedCrossRefGoogle Scholar
  7. 7.
    Kenyon GL and Garcia GA: Design of kinase inhibitors. Med Res Rev 1987 (7):389–416PubMedCrossRefGoogle Scholar
  8. 8.
    Levitski A: Tyrphostins — potential antiproliferative agents and novel molecular tools. Biochem Pharmac 1990 (40):313–318Google Scholar
  9. 9.
    Chang C-J and Geahlen RL: Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents. J Natural Products 1992 (11):1529–1560CrossRefGoogle Scholar
  10. 10.
    Workman P, Brunton VG, Robins DJ: Tyrosine kinase inhibitors. Sem Cancer Biol 1992 (3):369–381Google Scholar
  11. 11.
    Burke TR: Protein-tyrosine kinase inhibitors. Drugs of the Future 1992 (17):119–131Google Scholar
  12. 12.
    Spence P: Inhibitors of tyrosine kinase activity as anticancer therapeutics: recent developments. Current Opinion in Therapeutic Patents, December 1992Google Scholar
  13. 13.
    Dobrusin EM and Fry DW: Protein tyrosine kinases and cancer. Ann Rep Med Chem 1992 (27):169–176CrossRefGoogle Scholar
  14. 14.
    Hunter T: A thousand and one protein kinases. Cell 1987(50):823–829PubMedCrossRefGoogle Scholar
  15. 15.
    Gescher A: Towards selective pharmacological modulation of protein kinase C — opportunities for the development of novel antineoplastic agents. Br J Cancer 1992 (66):10–19PubMedCrossRefGoogle Scholar
  16. 16.
    Grunicke HH and Uberall F: Protein kinase C modulation. Sem Cancer Biology 1992 (3):351–360Google Scholar
  17. 17.
    Fantl W, Johnson DE, Williams RT: Signalling by receptor tyrosine kinases. Ann Rev Biochem 1993 (62):453–481PubMedCrossRefGoogle Scholar
  18. 18.
    Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987 (235):177–181PubMedCrossRefGoogle Scholar
  19. 19.
    Slamon DJ, Godolphin W, Jones LA et al: Studies of HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989 (244):707–712PubMedCrossRefGoogle Scholar
  20. 20.
    Bicknell R and Harris AL: Anticancer strategies involving vasculature: vascular targeting and the inhibition of angiogenesis. Sem Cancer Biology 1992(3):399–407Google Scholar
  21. 21.
    Bolen JB, Veillette A, Schwartz A, DeSeau V, Rosen N: Activation of pp60c-src protein kinase activity in human colon carcinoma. Proc Natl Acad Sci 1987 (84) :2251–2255PubMedCrossRefGoogle Scholar
  22. 22.
    Ottenhoff-Kalff AE, Rijksen G, van Bearden EACM, Hennipman A, Michels AA, Staal GEJ: Characterization of protein tyrosine kinases from human breast cancer: Involvement of the c-src oncogene product. Cancer Res 1992 (52):4773–4778Google Scholar
  23. 23.
    Shtivelman E, Lifshitz B, Gale RP, Canaani E: Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 1985 (315):550–554PubMedCrossRefGoogle Scholar
  24. 24.
    Ullrich A and Schlessinger J: Signal transduction by receptors with tyrosine kinase activity. Cell 1990 (61):203–213PubMedCrossRefGoogle Scholar
  25. 25.
    Snyder MA, Bishop JM, McGrath JP, Levinson AD: A mutation at the ATP-binding site of pp60c-src abolishes kinase activity, transformation, and tumorigenicity. Mol Cell Biol 1985 (5):1772–1779PubMedGoogle Scholar
  26. 26.
    Stein PL, Imamoto A, Soriano P: Genetic analysis of src-family tyrosine kinase mouse mutants. Proc Am Assoc Cancer Res 1993 (34):575Google Scholar
  27. 27.
    Hanks SK, Quinn AM, Hunter T: The protein kinase family: conserved features and deduced phytogeny of the catalytic domains. Science 1988 (241):42–52PubMedCrossRefGoogle Scholar
  28. 28.
    Knighton DR, Zheng J, Ten Eyck LF, Ashford VA, Xuong N-H, Taylor SS, Sowadski JM: Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science 1991 (253):407–414PubMedCrossRefGoogle Scholar
  29. 29.
    Zheng J, Knighton DR, Ten Eyck LF, Karlsson R, Xuong N-H, Taylor S, Sowadski JM: Crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MgATP and peptide inhibitor. Biochemistry 1993 (32):2154–2161PubMedCrossRefGoogle Scholar
  30. 30.
    Bossemeyer D, Engh RA, Kinzel V, Ponstinyl H, Huber R: Phosphotransferase and substrate binding mechanism of the cAMP-dependent protein kinase catalytic subunit from porcine heart as deduced from the 2.0 Å structure of the complex with Mn2+ adenyl imidophosphate and inhibitor peptide PKI (5–24). EMBO J 1993 (3):849–859Google Scholar
  31. 31.
    De Bondt HL, Rosenblatt J, Jancarik J, Jones HD, Morgan DO, Kim S-H: Crystal structure of cyclin-dependent kinase 2. Science 1993 (363):595–603Google Scholar
  32. 32.
    Knighton DR, Cadena DL, Zheng J, Ten Eyck LF, Taylor SS, Sowadski JM, Gill GN: Structural features that specify tyrosine kinase activity deduced from homology modelling of the epidermal growth factor receptor. Proc Natl Acad Sci 1993 (90):5001–5005PubMedCrossRefGoogle Scholar
  33. 33.
    Robinson S, Dean BJ, Petty BA: Characterization of A431 tumor xenograft as an in vivo model for testing epidermal growth factor-receptor antagonists. Int J Oncol 1992 (1):293–298PubMedGoogle Scholar
  34. 34.
    Hagiwara M, Inoue S, Tanaka T, Nunoki K, Ito M, Hidaka H: Differential effects of flavonoids as inhibitors of tyrosine protein kinases and serine/ threonine protein kinases. Biochem Pharmac 1988 (37):2987–2992CrossRefGoogle Scholar
  35. 35.
    Okura A, Arakawa H, Oka H, Yoshinari T, Moden Y: Effect of genistein on topoisomerase activity and on the growth of Ha-ras-transformed NIH3T3 cells. Biochem Biophys Res Comm 1988 (157):183–189PubMedCrossRefGoogle Scholar
  36. 36.
    Cushman M, Nagarathnam D, Burg DL, Geahlen RL: Synthesis and protein tyrosine kinase inhibitory activities of flavonoid analogues. J Med Chem 1991 (34):798–806PubMedCrossRefGoogle Scholar
  37. 37.
    Worland PJ, Kaur G, Stetler-Stevenson M, Sebers S, Sartor O, Sausville EA: Alteration of a p34cdc2 kinase by the flavone L86–8275 in breast carcinoma cells. Biochem Pharmac 1993 (46):1831–1840CrossRefGoogle Scholar
  38. 38.
    Geahlen RL and McLaughlin JL: Piceatannol (3,4,5′-tetrahydroxy-trans-stilbene) is a naturally occurring protein-tyrosine kinase inhibitor. Biochem Biophys Res Comm 1989 (165):241–245PubMedCrossRefGoogle Scholar
  39. 39.
    Cunningham BDM, Threadgill MD, Groundwater PW, Dale IL, Hickman JA: Synthesis and biological evaluation of protein tyrosine kinases. Anti-Cancer Drug Design 1992 (7):365–384PubMedGoogle Scholar
  40. 40.
    Umezawa H, Imoto M, Sawa T, Isshiki K, Matsuda N, Uchida T, Iinuma H, Hamada H, Hamada M, Takeuchi T: Studies on a new epidermal growth factor receptor kinase inhibitor, erbstatin, produced by MH 435-hF3. J Antibiot 1986 (39):170–173PubMedGoogle Scholar
  41. 41.
    Yaish P, Gazit A, Gilon C, Levitski A: Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science 1988 (242):933–935PubMedCrossRefGoogle Scholar
  42. 42.
    Gazit A, Osherov N, Posner I, Yaish P, Pradosy E, Gilon C, Levitski A: Tyrphostins 2. Heterocyclic and alpha-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and erbB2/neu tyrosine kinases. J Med Chem 1991 (34):1897–1907CrossRefGoogle Scholar
  43. 43.
    Brunton VG, Lear MJ, Robins DJ, Williamson S, Workman P: Synthesis and antiproliferative activity of tyrphostins containing heteroaromatic moieties. Anti-Cancer Drug Design 1994 (in press)Google Scholar
  44. 44.
    Yoneda T, Lyall RM, Alsina MM, Persons PE, Spada AP, Levitski A, Zilbertstein A, Mundy GR: The antiproliferative effects of tyrosine kinase inhibitors tyrphostins and a human squamous cell carcinoma in vitro and in nude mice. Cancer Res 1991 (51):4430–4435PubMedGoogle Scholar
  45. 45.
    Shiraishi T, Domoto T, Imai N, Shimada Y, Watanabe K: Specific inhibitors of tyrosine specific protein kinase, synthetic 4-hydroxycinnamamide derivatives. Biochem Biophys Res Comm 1987 (147):322–328PubMedCrossRefGoogle Scholar
  46. 46.
    Traxler PM, Wacker O, Bach HL, Geissler JF, Kump W, Meyer T, Regenass U, Roesel JL, Lydon N: Sulfonylbenzoylnitrostyrenes: potential bisubstrate type inhibitors of the EGF-receptor tyrosine kinase. J Med Chem 1991 (34):2328–2337PubMedCrossRefGoogle Scholar
  47. 47.
    Geissler JF, Traxler P, Regenass U, Murray BJ, Roessel JL, Meyer T, McGlynn E, Storni A, Lydon NB: Thiazolidine-diones. Biochemical and biological activity of a novel class of tyrosine protein kinase inhibitors. J Biol Chem 1990 (265):22255–22261PubMedGoogle Scholar
  48. 48.
    Traxler P, Buchdunger E, Mett H, Meyer T, Regenass U, Roesel J, Trinks U, Lydon N: Amino-alkyl-acrylophenones as potent and selective inhibitors of the EGF-receptor protein tyrosine kinase. Proc Am Assoc Cancer Res 1992 (33):527Google Scholar
  49. 49.
    Kraker AJ, Wemple, Schemmel ME, Moore CW: Inhibition of epidermal growth factor receptor tyrosine kinase by 2-thioindoles, a new structural class of tyrosine kinase inhibitor. Proc Am Assoc Cancer Res 1993 (34):408Google Scholar
  50. 50.
    Lydon N, Buchdunger E, Mett H, Regenass U, Muller M, Trinks U, Traxler P: Biological profile of CGP 52411: a tyrosine protein kinase inhibitor with selectivity for the EGF-receptor enzyme family. J Cell Biochem Suppl 1993 (17A):235Google Scholar
  51. 51.
    Buchdunger F et al: 4,5-dianilino-phthalimide: a novel tyrosine protein kinase inhibitor with selectivity for the EGF receptor signal transduction pathway and potent in vivo antitumour activity. Proc Natl Acad Sci 1994 (in press)Google Scholar
  52. 52.
    Uchara Y, Hori M, Takeuchi T, Umezawa H: Screening of agents which convert ‘transformed morphology’: identification of an active agent as herbimycin and its inhibition of intracellular src kinase. Jpn J Cancer Res 1985 (76):672–675Google Scholar
  53. 53.
    Uchara Y, Fukazawa H, Murakami Y, Mizuno S: Irreversible inhibition of v-src tyrosine kinase activity by herbimycin A and its abrogation by sulphydryl compounds. Biochem Biophys Res Comm 1989 (163):803–809CrossRefGoogle Scholar
  54. 54.
    Hamaguchi M, Xiao H, Uchara Y, Ohnishi Y, Nagai Y: Herbimycin A inhibits the association of p60v-src with the cytoskeletal structure and with phospha-tidylinositol 3′kinase. Oncogene 1993 (8):559–564PubMedGoogle Scholar
  55. 55.
    Pelech L: Networking with protein kinases. Current Biology 1993 (3):513–515PubMedCrossRefGoogle Scholar
  56. 56.
    Moodie SA and Wolfman A: The 3 Rs of life: Ras, raf and growth regulation. Trends Genetics 1994 (10):44–48CrossRefGoogle Scholar
  57. 57.
    Pawson T and Schlessinger J: SH2 and SH3 domains. Current Biology 1993 (3):434–442PubMedCrossRefGoogle Scholar
  58. 58.
    Songyang Z, Schoelson SE, Chaudhuri M et al: SH2 domains recognize specific phosphopeptide sequences. Cell 1983 (72):767–778Google Scholar
  59. 59.
    McNamara DJ, Dobrusin E, Zhu G, Decker SJ, Saltiel AR: Inhibition of the binding of phospholipase Cγ1 SH2 domains to phosphorylated epidermal growth factor receptor by phosphorylated peptides. Int J Peptide Protein Res 1993 (42):240–248CrossRefGoogle Scholar
  60. 60.
    McCormick F: How receptors turn ras on. Nature 1993(363):15–16PubMedCrossRefGoogle Scholar
  61. 61.
    Wu J, Dent P, Jelinek T, Wolfman A, Weber M, Sturgill TW: Inhibition of the EGF-activated MAP kinase signalling pathway by adenosine 3′,5′-mono-phosphate. Science 1993 (262):1065–1069PubMedCrossRefGoogle Scholar
  62. 62.
    Cook SJ and McCormick F: Inhibition by cAMP of ras-dependent activation of raf. Science 1993 (262):1069–1072PubMedCrossRefGoogle Scholar
  63. 63.
    Graves LM, Bomfeldt KE, Raines EW, Potts BC, MacDonald SG, Ross R, Krebs EG: Protein kinase A antagonizes platelet-derived growth factor-induced signalling by mitogen-activated protein kinase in human arterial smooth muscle cells. Proc Natl Acad Sci USA 1993 (90):10300–10304PubMedCrossRefGoogle Scholar
  64. 64.
    Silvennoinen O, Schindler C, Schlessinger J, Levy DE: Ras-independent growth factor signalling by transcription factor tyrosine phosphorylation. Science 1993 (261):1736–1739PubMedCrossRefGoogle Scholar
  65. 65.
    Sadowski HB, Shuai K, Darnell JE, Gilman MZ: A common nuclear signal transduction pathway activated by growth factor and cytokine receptors. Science 1993 (261):1739–1743PubMedCrossRefGoogle Scholar
  66. 66.
    Fu X-Y and Zhang J-J: Transcription factor p91 interacts with the epidermal growth factor receptor and mediates activation of the c-fos gene promoter. Cell 1993 (74):1135–1145PubMedCrossRefGoogle Scholar
  67. 67.
    Bos JL: Ras oncogenes and human cancer: A review. Cancer Res 1989 (49):4682–4689PubMedGoogle Scholar
  68. 68.
    James GL, Goldstein JL, Brown MS et al: Benzodiazepine peptidomimetics: Potent inhibitors of ras famesylation in animal cells. Science 1993 (260):1937–1942PubMedCrossRefGoogle Scholar
  69. 69.
    Kohl NE, Mosser SD, de Solms J, Giuliani EA, Pompliano DL, Graham SL, Smith RL, Scolnick EM, Oliff A, Gibbs JB: Selective inhibition of ras- dependent transformation by a farnesyltransferase inhibitor. Science 1993 (260):1934–1937PubMedCrossRefGoogle Scholar
  70. 70.
    Waksman G, Kominos D, Robertson SC et al: Crystal structure of the phosphotyrosine recognition domain SH2 of v-src complexed with tyrosine-phosphorylated peptides. Nature 1992 (358):646–653PubMedCrossRefGoogle Scholar
  71. 71.
    Kerr JFR, Wyllie AH, Currie AR: Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinetics. Br J Cancer 1972 (26):239–157PubMedCrossRefGoogle Scholar
  72. 72.
    Wyllie AH, Kerr JFR, Currie AR: Cell death: the significance of apoptosis. Int Rev Cytol 1980 (68): 251–300PubMedCrossRefGoogle Scholar
  73. 73.
    Dive C, Evans CE, Whetton AD: Induction of apoptosis — new targets for cancer chemotherapy. Sem Cancer Biology 1992 (3):417–427Google Scholar
  74. 74.
    Raff M: Social controls on cell survival and death. Nature 1992 (356):397–400PubMedCrossRefGoogle Scholar
  75. 75.
    Fanidi A, Harrington EA, Evan GI: Cooperative interaction between c-myc and bcl-2 oncogene. Nature 1992 (359):554–556PubMedCrossRefGoogle Scholar
  76. 76.
    Workman P and Graham MA: Pharmacokinetics of Cancer Chemotherapy. Cancer Surveys, Vol 17. Cold Spring Harbor, 1993Google Scholar
  77. 77.
    Zachary I and Rozengurt E: Focal adhesion kinase (p125FAK): A point of convergence in the action of neuropeptides, integrins and oncogenes. Cell 1992 (71):891–894PubMedCrossRefGoogle Scholar
  78. 78.
    Weiner TM, Liu EJ, Craven RJ Cance WG: Expression of focal adhesion kinase gene and invasive cancer. Lancet 1993 (342):1024–1025PubMedCrossRefGoogle Scholar
  79. 79.
    Millauer B, Shawver LK, Plate KH, Risan W, Ullrich A: Glioblastoma growth inhibited in vivo by a dominant-negative flk-1 mutant. Nature 1994 (367):576–579PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • Paul Workman
    • 1
  • Valerie G. Brunton
    • 1
  • David J. Robins
    • 2
  1. 1.Cancer Research Campaign Department of Medical OncologyUniversity of Glasgow, CRC Beatson LaboratoriesBearsden, GlasgowUK
  2. 2.Department of ChemistryUniversity of GlasgowGlasgowUK

Personalised recommendations